Literature DB >> 26798373

Community pharmacist targeted screening for chronic kidney disease.

Yazid N Al Hamarneh1, Brenda Hemmelgarn1, Craig Curtis1, Carlee Balint1, Charlotte A Jones1, Ross T Tsuyuki1.   

Abstract

Entities:  

Year:  2016        PMID： 26798373      PMCID： PMC4713893          DOI： 10.1177/1715163515618421

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  13 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Online clinical pathway for managing adults with chronic kidney disease.

Authors:  Craig Curtis; Carlee Balint; Yazid N Al Hamarneh; Maoliosa Donald; Ross T Tsuyuki; Kerry McBrien; Wes Jackson; Brenda Hemmelgarn
Journal:  Can Pharm J (Ott)       Date:  2015-09

3.  Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative.

Authors:  Sheldon W Tobe; James A Stone; Melissa Brouwers; Onil Bhattacharyya; Kimberly M Walker; Martin Dawes; Jacques Genest; Steven Grover; Gordon Gubitz; David Lau; Andrew Pipe; Peter Selby; Mark S Tremblay; Darren E R Warburton; Richard Ward; Vincent Woo; Lawrence A Leiter; Peter P Liu
Journal:  CMAJ       Date:  2011-09-12       Impact factor: 8.262

4.  The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Authors:  Daniel G Hackam; Robert R Quinn; Pietro Ravani; Doreen M Rabi; Kaberi Dasgupta; Stella S Daskalopoulou; Nadia A Khan; Robert J Herman; Simon L Bacon; Lyne Cloutier; Martin Dawes; Simon W Rabkin; Richard E Gilbert; Marcel Ruzicka; Donald W McKay; Tavis S Campbell; Steven Grover; George Honos; Ernesto L Schiffrin; Peter Bolli; Thomas W Wilson; Ross D Feldman; Patrice Lindsay; Michael D Hill; Mark Gelfer; Kevin D Burns; Michel Vallée; G V Ramesh Prasad; Marcel Lebel; Donna McLean; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Jean-Martin Boulanger; Pierre Larochelle; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Janusz Kaczorowski; Luc Trudeau; Robert J Petrella; Alain Milot; James A Stone; Denis Drouin; Kim L Lavoie; Maxime Lamarre-Cliche; Marshall Godwin; Guy Tremblay; Pavel Hamet; George Fodor; S George Carruthers; George B Pylypchuk; Ellen Burgess; Richard Lewanczuk; George K Dresser; S Brian Penner; Robert A Hegele; Philip A McFarlane; Mukul Sharma; Debra J Reid; Sheldon W Tobe; Luc Poirier; Raj S Padwal
Journal:  Can J Cardiol       Date:  2013-03-29       Impact factor: 5.223

5.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.

Authors:  Alice Y Y Cheng
Journal:  Can J Diabetes       Date:  2013-03-26       Impact factor: 4.190

7.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

Review 8.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

9.  Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey.

Authors:  Paul Arora; Priya Vasa; Darren Brenner; Karl Iglar; Phil McFarlane; Howard Morrison; Alaa Badawi
Journal:  CMAJ       Date:  2013-05-06       Impact factor: 8.262

10.  Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease).

Authors:  Lynda A Szczech; Rebecca C Stewart; Hsu-Lin Su; Richard J DeLoskey; Brad C Astor; Chester H Fox; Peter A McCullough; Joseph A Vassalotti
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240
View more
  7 in total

1.  Pharmacy practice research produces findings that inform how pharmacists contribute to optimal drug therapy outcomes for Canadians.

Authors:  Lisa Dolovich; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-08-08

Review 2.  Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review.

Authors:  Pankti A Gheewala; Syed Tabish R Zaidi; Matthew D Jose; Luke Bereznicki; Gregory M Peterson; Ronald L Castelino
Journal:  J Nephrol       Date:  2017-02-08       Impact factor: 3.902

3.  Community pharmacist identification of chronic kidney disease using point-of-care technology: A pilot study.

Authors:  Jacqueline Donovan; Yazid N Al Hamarneh; Beata Bajorek; John Papastergiou; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2020-02-13

Review 4.  The community pharmacist's role in cancer screening and prevention.

Authors:  Anthony James Havlicek; Holly Mansell
Journal:  Can Pharm J (Ott)       Date:  2016-07-29

5.  Development and Application of the GheOP3S-Tool Addendum on Potentially Inappropriate Prescribing (PIP) of Renally Excreted Active Drugs (READs) in Older Adults with Polypharmacy.

Authors:  Abdul Aziz Al Wazzan; Eline Tommelein; Katrien Foubert; Stefano Bonassi; Graziano Onder; Annemie Somers; Mirko Petrovic; Koen Boussery
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

Review 6.  Barriers to a full scope of pharmacy practice in primary care: A systematic review of pharmacists' access to laboratory testing.

Authors:  Jacqueline Donovan; Ross T Tsuyuki; Yazid N Al Hamarneh; Beata Bajorek
Journal:  Can Pharm J (Ott)       Date:  2019-08-06

7.  Enhancing primary care capacity in chronic kidney disease management: a quality improvement educational initiative.

Authors:  Michelle D Smekal; Aminu K Bello; Maoliosa Donald; Deenaz Zaidi; Kerry McBrien; Katrina Nicholson; Ellen Novak; Brenda Hemmelgarn
Journal:  BMJ Open       Date:  2021-11-09       Impact factor: 3.006
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.